Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CEO Sanj Patel sold 2,141 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $54.01, for a total value of $115,635.41. Following the sale, the chief executive officer directly owned 431,904 shares in the company, valued at approximately $23,327,135.04. This trade represents a 0.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kiniksa Pharmaceuticals International Trading Up 1.5%
KNSA opened at $53.78 on Friday. The business's 50 day moving average is $46.40 and its 200-day moving average is $43.12. The stock has a market cap of $4.12 billion, a PE ratio of 59.76 and a beta of 0.06. Kiniksa Pharmaceuticals International, plc has a twelve month low of $24.85 and a twelve month high of $54.31.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.09. The company had revenue of $214.27 million for the quarter, compared to analysts' expectations of $206.11 million. Kiniksa Pharmaceuticals International had a return on equity of 13.72% and a net margin of 9.69%.The business's revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.11 earnings per share. As a group, analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.17 EPS for the current year.
Key Kiniksa Pharmaceuticals International News
Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:
- Positive Sentiment: Q1 beat and raised guidance — Kiniksa reported $0.27 EPS vs. $0.18 consensus and revenue of $214.3M (≈+55.5% YoY); management raised FY‑2026 revenue guidance to $930M–$945M, improving near‑term revenue visibility. Read More.
- Positive Sentiment: Analyst upgrades/target raises — Multiple brokers lifted ratings and targets (examples: Jefferies to $71, Canaccord to $64, Citi to $60, Wedbush to $59, Wells Fargo to $57), signaling higher earnings/revenue expectations and encouraging flows. Read More.
- Positive Sentiment: Product momentum — ARCALYST reported strong net product revenue in Q1 and management increased 2026 expectations; this supports revenue durability and valuation expansion. Read More.
- Positive Sentiment: Pipeline catalysts ahead — KPL‑387 Phase 2 recurrent pericarditis data expected in 2H‑2026 with a planned Phase 3 start by year‑end; upcoming readouts could be material share‑price catalysts. Read More.
- Neutral Sentiment: Earnings materials available — Q1 slide deck and call transcript posted; useful for validating channel dynamics, margin assumptions and guidance drivers. Read More.
- Negative Sentiment: Large CEO selling — CEO Sanj K. Patel sold 483,654 shares on Apr. 28 (avg ~$51.86) and additional smaller tranches Apr. 29–30 under a pre‑arranged 10b5‑1 plan; this reduced his reported stake materially and may weigh on sentiment despite the plan. Read More.
- Negative Sentiment: Director sale — Director Barry D. Quart sold 13,099 shares (~$50.10 avg) under a 10b5‑1 plan, cutting his holding ~51%; insider selling can add short‑term pressure even when pre‑planned. Read More.
Analyst Ratings Changes
A number of research analysts recently commented on KNSA shares. Citigroup raised their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a "buy" rating in a research note on Wednesday. Wells Fargo & Company raised their price objective on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an "overweight" rating in a research note on Wednesday. Weiss Ratings reiterated a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a research note on Tuesday, April 21st. Jefferies Financial Group raised their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a "buy" rating in a research note on Tuesday. Finally, Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "hold" rating in a research note on Sunday, April 26th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $60.86.
Get Our Latest Stock Analysis on Kiniksa Pharmaceuticals International
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in KNSA. Qube Research & Technologies Ltd grew its position in Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company's stock worth $24,581,000 after buying an additional 653,236 shares during the last quarter. Rubric Capital Management LP grew its position in Kiniksa Pharmaceuticals International by 15.6% in the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company's stock worth $108,184,000 after buying an additional 526,567 shares during the last quarter. Cubist Systematic Strategies LLC grew its position in Kiniksa Pharmaceuticals International by 213.2% in the second quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company's stock worth $18,192,000 after buying an additional 447,536 shares during the last quarter. Spruce Street Capital LP acquired a new position in Kiniksa Pharmaceuticals International in the fourth quarter worth approximately $17,943,000. Finally, SG Americas Securities LLC grew its position in Kiniksa Pharmaceuticals International by 288.6% in the fourth quarter. SG Americas Securities LLC now owns 541,396 shares of the company's stock worth $22,333,000 after buying an additional 402,078 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.
Kiniksa Pharmaceuticals International Company Profile
(
Get Free Report)
Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.
The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
